Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Inv. presentation
Acq. announced
NeurogesX Inc (NGSX) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/13/2017 SC 13G/A Henriques Charles A. reports a 15% stake in NeurogesX, Inc.
02/09/2017 SC 13G/A KCG AMERICAS LLC reports a 5.1% stake in NeurogesX, Inc.    
02/17/2016 SC 13G/A Henriques Charles A. reports a 13.8% stake in NeurogesX, Inc.
07/11/2013 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
06/24/2013 8-K Quarterly results
04/17/2013 8-K Acquisition/merger/asset purchase announced
03/27/2013 8-K SEC Filing in the EDGAR database
03/27/2013 EFFECT Form EFFECT - Notice of Effectiveness
03/27/2013 EFFECT Form EFFECT - Notice of Effectiveness
03/27/2013 EFFECT Form EFFECT - Notice of Effectiveness
03/27/2013 EFFECT Form EFFECT - Notice of Effectiveness
03/25/2013 POS AM Form POS AM - Post-Effective amendments for registration statement
03/25/2013 POS AM Form POS AM - Post-Effective amendments for registration statement
03/25/2013 POS AM Form POS AM - Post-Effective amendments for registration statement
03/25/2013 POS AM Form POS AM - Post-Effective amendments for registration statement
03/11/2013 8-K Entry into a Material Definitive Agreement, Other Events
03/05/2013 8-K Cost Associated with Exit or Disposal Activities, Other Events
01/08/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/30/2012 8-K Cost Associated with Exit or Disposal Activities, Other Events
11/14/2012 10-Q Quarterly Report for the period ended September 30, 2012
11/14/2012 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
09/14/2012 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
09/14/2012 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
08/30/2012 GN NeurogesX' NGX-1998 Well-Tolerated Treatment Demonstrated Clear Dose-Response in Patients
08/24/2012 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
08/10/2012 10-Q Quarterly Report for the period ended June 30, 2012
08/07/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "NeurogesX Provides Regulatory Update For NGX-1998 Clinical Program End-of Phase 2 FDA Guidance Supports Plan To Enter Phase 3 Development Later This Year San Mateo, Calif., - NeurogesX, Inc. , a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today provided an update on its regulatory process for NGX-1998, the Company's next generation liquid formulation of prescription-strength capsaicin. NeurogesX recently received End-of-Phase 2 guidance from the U.S. Food and Drug Administration regarding its previously announced plans for the Phase 3 clinical development of NGX-1998 as a treatment for neuropathic pain conditions, including key elements of its overall development plan related to manufacturing, applic..."
08/07/2012 GN NeurogesX Provides Regulatory Update for NGX-1998 Clinical Program
08/03/2012 8-K Quarterly results
Docs: "NeurogesX Reports Second Quarter 2012 Results Q2 2012 and Recent Highlights:"
08/03/2012 GN NeurogesX Reports Second Quarter 2012 Results
08/02/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "NeurogesX Receives Additional Notice of Allowance Covering NGX-1998 in U.S. San Mateo, Calif., - NeurogesX, Inc. , a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced it has received an additional notice of allowance from the United States Patent and Trademark Office related to the company's family of patents for NGX-1998, the Company's next generation liquid formulation of prescription-strength capsaicin. The allowed patent application expands on the Company's patent entitled, “Methods and compositions for administration of TRPV1 agonists.” The claims in the allowed application relate to methods of treating capsaicin-responsive conditions with a liquid formulation containing between 10% an..."
07/27/2012 GN NeurogesX to Hold Conference Call to Discuss Second Quarter 2012 Results
07/16/2012 GN NeurogesX NGX-1998 Phase 2 Study Data to be Presented at World Congress on Pain
06/29/2012 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy